Teriparatide vs MK-677 (Ibutamoren)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →MK-677 (Ibutamoren)
MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.
Full details →Side-by-Side Comparison
| Aspect | Teriparatide | MK-677 (Ibutamoren) |
|---|---|---|
| Mechanism | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. | Acts as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects. |
| Typical Dosage | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. | Typical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase. |
| Administration | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. | Oral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing. |
| Side Effects | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. | Increased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity. |
| Best For |
What They Have in Common
Both Teriparatide and MK-677 (Ibutamoren) are commonly used for: